No. 13-29

May 17, 2013
Eisai Co., Ltd.

EISAI TO PRESENT NEW RESEARCH ON ONCOLOGY PRODUCTS AND PIPELINE AT 49TH ASCO ANNUAL MEETING

Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito, "Eisai") announced today that a series of abstracts highlighting new study results on Halaven® (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor) and lenvatinib (generic name; VEGF receptor tyrosine kinase inhibitor and multikinase inhibitor) will be presented during the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2013.

This year's ASCO meeting will include presentations highlighting the results of subgroup analyses and quality of life (QOL) research into a head-to-head study of Halaven versus capecitabine (Study 301) that was conducted in 1,102 patients with locally advanced or metastatic breast cancer, as well as the results of Phase II studies of lenvatinib in patients with endometrial cancer and melanoma.

Eisai positions oncology as a key franchise area. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, and in doing so seeks to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families as well as healthcare providers.

Major Eisai abstracts accepted for presentation at this year's ASCO meeting include:

Product	Abstract title and scheduled presentation date and time (local time)
Eribulin Mesylate (Halaven®) Abstract No: 1049	A Phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: subgroup analyses. ***Poster Presentation*** | June 1 (Sat), 13:15-17:00
Eribulin Mesylate (Halaven®) Abstract No: 1050	Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A Phase III, open-label, randomized study. ***Poster Presentation*** | June 1 (Sat), 13:15-17:00
Eribulin Mesylate (Halaven®) Abstract No: 1055	Quality of life (QoL) and content validity in objective tumor response. ***Poster Presentation*** | June 1 (Sat), 13:15-17:00
Eribulin Mesylate (Halaven®) Abstract No: 563	Eribulin mesylate (Erib) plus capecitabine (X) for adjuvant treatment in post-menopausal estrogen receptor-positive (ER+) early-stage breast cancer: Phase II, multicenter, single-arm study. ***Poster Presentation*** | June 1 (Sat), 13:15-17:00

(continued on following page)

Lenvatinib (E7080) Abstract No: 5520	A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: Angiopoietin-2 as a predictive marker for clinical outcomes. ***Poster Discussion Session*** | June 2 (Sun), Display: 08:00-12:00, Discussion: 11:30-12:30
Lenvatinib (E7080) Abstract No: 5591	Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer. ***Poster Presentation*** | June 3 (Mon), 08:00-11:45
Lenvatinib (E7080) Abstract No: 9026	A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. ***Poster Discussion Session*** | June 3 (Mon), Display: 08:00-12:00, Discussion: 11:30-12:30
Lenvatinib (E7080) Abstract No: 9058	Analysis of serum biomarkers and tumor genetic alterations from phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma. ***Poster Presentation*** | June 1 (Sat), 08:00-11:45
Lenvatinib (E7080) Abstract No: 9027	Lenvatinib combined with dacarbazine versus dacarbazine alone as first-line treatment in patients with stage IV melanoma. ***Poster Discussion Session*** | June 3 (Mon), Display: 08:00-12:00, Discussion: 11:30-12:30

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120